CAR-T cell therapy harnesses the immune system to attack blood cancers. Six years after approving the first treatment, the FDA is investigating whether it can give rise to secondary cancers. Wired Read More
CAR-T cell therapy harnesses the immune system to attack blood cancers. Six years after approving the first treatment, the FDA is investigating whether it can give rise to secondary cancers.
